iwMyeloma 2015 | Minimal residue disease (MRD) in multiple myeloma
Rafael Fonseca • 11 Apr 2015
At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) considers how detecting and monitoring minimal residue disease (MRD) in multiple myeloma may inform and tailor therapeutic decisions. Clinically important methods to determine MRD include flow cytometry and next-generation sequencing.
